WFRF:(Hagell P.)
Search: WFRF:(Hagell P.) > Apomorphine formula...
- 5 of 56
- Previous record
- Next record
- To hitlist
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
-
- Hagell, Peter (author)
- Högskolan Kristianstad,Forskningsmiljön PRO-CARE, Patient Reported Outcomes - Clinical Assessment Research and Education,Avdelningen för sjuksköterskeutbildningarna och integrerad hälsovetenskap
-
- Höglund, Arja (author)
- Karolinska universitetssjukhuset
-
- Hellqvist, Carina (author)
- Universitetssjukhuset i Linköping
- show more...
- Karlberg, C (author)
- Hellqvist, C (author)
- Lowed, B (author)
- Willows, T (author)
- Radberg, J (author)
- Bergquist, F (author)
- Dizdar, N (author)
- Lundgren, M (author)
- Hagell, P (author)
- Sjostrom, AC (author)
- Johansson, EL (author)
- show less...
- (creator_code:org_t)
- 2020
- 2020
- English.
- In: Journal of Neurology. - 0340-5354 .- 1432-1459. ; 267:11, s. 3411-3417
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
Subject headings
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
Keyword
- Apomorphin; Complications; Nodules; Parkinson’s disease; Safety; Skin
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Journal of Neurology (Search for host publication in LIBRIS)
To the university's database
- 5 of 56
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Hagell, Peter
- Höglund, Arja
- Hellqvist, Carin ...
- Johansson, Eva-L ...
- Löwed, Berit
- Sjöström, Anne-C ...
- show more...
- Karlberg, Carina
- Lundgren, Margar ...
- Dizdar, Nil
- Johansson, Ander ...
- Willows, Thomas
- Rådberg, Johan
- Bergquist, Filip
- Karlberg, C
- Hellqvist, C
- Lowed, B
- Willows, T
- Radberg, J
- Bergquist, F
- Dizdar, N
- Hoglund, A
- Lundgren, M
- Hagell, P
- Sjostrom, AC
- Johansson, EL
- Johansson, A
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- Articles in the publication
- Journal of Neuro ...
- By the university
- Kristianstad University College
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
